Cooley Shortlisted for Multiple LMG Life Sciences EMEA Awards

London – April 23, 2025 – Cooley’s London- and Brussels-based life sciences practice has been shortlisted for multiple awards by LMG Life Sciences EMEA (Europe, the Middle East and Africa).

The firm was shortlisted for two practice area awards – Licensing & Collaboration Firm of the Year and Venture Capital Firm of the Year. Additionally, two London-based lawyers were shortlisted: Frances Stocks Allen as Licensing & Collaboration Lawyer of the Year and Russell Anderson as M&A Lawyer of the Year.

An awards ceremony will be held in London on June 5.

In 2024, LMG Life Sciences EMEA named Cooley the Venture Capital Firm of the Year, recognized the firm on four Impact Deals of the Year, and honored associate Mark Jones as a Financial Rising Star.

LMG Life Sciences produces one of the most respected awards programs for life sciences practitioners and firms in the US, Canada, Europe, the Middle East and Africa. Winners are determined through a rigorous research process that aims to survey excellent legal service over a 12-month period. Four key practice areas are covered in the award categories – financial and corporate, regulatory, intellectual property (IP), and non-IP litigation and enforcement.

Life sciences breakthroughs happen with Cooley. The firm’s collaborative approach draws upon unparalleled life sciences sector experience to drive strategic solutions and resolve challenges.

The firm’s practitioners are versed in all aspects of life sciences technologies, delivering an unmatched combination of innovative legal guidance, deep industry knowledge and practical understanding of clients’ needs. Many of our lawyers worked as pharmaceutical marketing professionals, business consultants, financial leaders, biotech researchers and in-house counsel at life sciences companies before joining the Cooley team.

The firm is trusted counsel to 2,500+ public and private life sciences company clients worldwide, including nearly 50% of the Nasdaq Biotechnology Index. Clients include innovative biotech and specialty pharmaceutical companies at the forefront of new technologies, including cell and gene therapies, artificial intelligence-led drug discovery and new vaccine technologies.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.